ZEISS Asia-Pacific Ophthalmology Symposium Held in Shanghai, Experts Explore New Advances in Refractive Surgery

(Source: Shanghai Observation News)

Recently, the 2026 Carl Zeiss Asia-Pacific Ophthalmology Annual Meeting was held in Shanghai, focusing on the development trends of global cutting-edge ophthalmic technologies and clinical applications. During the conference,Bright EyeJointly host the SMILE pro User Conference and Refractive New Technology Academic Seminar with Carl Zeiss, focusing on core topics such as SMILE pro all-femtosecond technology and digital ophthalmic diagnosis and treatment, to build an international academic exchange platform and promote innovation and clinical implementation of refractive diagnosis and treatment technologies.

At the seminar, Professor Shen Zhengwei, Head of the Refractive Surgery Group at Bright Eye Hospital Group and Chief Director of Hubei Province, shared the next generationRobotThe Clinical Application Value and Standardized Application Key Points of SMILE Technology, the Empowering Role of Refractive Surgery Technology Upgrade in Clinical Diagnosis and Treatment, and the Development Concept of Bright Eye Optimizing Clinical Outcomes of Refractive Surgery and Improving Diagnostic Quality through Technological Innovation.

After years of in-depth耕耘 in the field of refractive treatment, Bright Eye continues to deepen its strategic cooperation with top international medical manufacturers such as Carl Zeiss, implementing mainstream and cutting-edge refractive technologies like SMILE pro full-femtosecond and ICL-V5 lens implantation, and building a nationwide refractive treatment service network in China. Relying on a mature clinical application and technical training system, the group has received the "SMILE Pro 11,000 Case Surgery Quality Pioneer" certification from German蔡司, accumulating sufficient clinical cases in the fields of full-femtosecond and ICL lens implantation surgeries, continuously promoting the standardization and normalization development of refractive surgeries in China.

As the core medical institution of Bright Eye Hospital Group, the Ophthalmology Center affiliated with Shanghai University School of Medicine (HepalinkBright Eye Hospital Group Co., Ltd. took the lead in introducing the new generation of Carl Zeiss robotic VisuMax™ 800 device, with a large clinical volume of SMILE pro and ICL-V5 lens implantation surgeries, ranking among the top in the group. It has cumulatively completed tens of thousands of refractive surgeries, accumulating rich clinical diagnosis and treatment experience.

In terms of diagnosis and treatment quality control, the hospital has established a professional refractive diagnosis and treatment physician team, building a full-process quality control system for refractive surgery that covers the entire treatment cycle, including preoperative examination and evaluation, intraoperative plan execution, and postoperative follow-up management. Equipped with specialized devices such as the Carl Zeiss ARTEVO 800 intraoperative navigation 3D digital microscope, the hospital also set up an ICL lens calculation center. Dr. Xiao Qirui, Associate Dean of Ophthalmology at Shanghai University School of Medicine Affiliated Eye Center (Shanghai Bright Eye Hospital), applies the "ICL One-Step Non-Adhesive Method" to provide technical support for efficient and minimally invasive clinical treatments. Relying on more than 20 preoperative specialized examinations and AI-assisted surgical planning systems, the hospital standardizes the refractive surgery process to ensure precision and safety. As one of the first clinical application cooperation centers for EVO+ICL (V5), the hospital continues to implement cutting-edge refractive technologies, offering patients standardized and personalized lens removal treatment solutions.

Original Title: "Carl Zeiss Asia-Pacific Ophthalmology Seminar Held in Shanghai, Experts from China and Abroad Join Hands to Explore New Developments in Refractive Surgery"

Column Editor: Gao Yang

Source: Author: Xinmin Evening News, Zuo Yan